Identification Of The Long Non-coding RNA In Plasma As A New Novel Biomarker For Early Diagnosis Of Pancreatic Cancer

Objective:Pancreatic cancer is a common digestive malignant tumor in China,which has a high degree of malignancy.Due to lack obvious clinical symptoms in early stage and without effective prevention and detection methods,so most patients have reached the advanced stage and have lost the opportunity for surgical treatment,but the effect of other therapy like radiotherapy and chemotherapy are poor and lead to low survival rate.Therefore,it is significanct to find reliable biomarkers for early diagnosis of pancreatic cancer.We screened for lncRNAs which expressed differentlly in pancreatic cancer patients through database,and evaluated lncRNAs can be used as a new molecular marker for the early diagnosis of pancreatic cancer in plasma,to provide basis for the research of the early diagnosis of pancreatic cancer.Methods:1.We analyzed The Cancer Genome Atlas(TCGA)database through the website cBioportal and 11 lncRNAs were screened out which were differentially expressed in pancreatic cancer.2.The expression levels of above 11 lncRNAs were further analyzed in the plasma of 30 non-tumor plasma samples(including 15 healthy and 15 chronic pancreatitis subjects)and 15 pancreatic cancer patients.3.Three candidate lncRNAs including ABHD11-AS1,LINC00176,and SNHG11 were further validated in 46 healthy controls,97 chronic pancreatitis patients,and 114 pancreatic cancer patient plasma samples.4.Receiver operating characteristic curve(ROC curve)was employed to evaluate the performance of the identified lncRNAs,especially early stage of pancreatic cancer.The TCGA database was analyzed through the website ONCOLNC to clarify the relationship between the expression of lnc RNA and the overall survival rate.Results:Our data show that the expression of three candidate lncRNAs,ABHD11-AS1,LINC00176 and SNHG11,were gradually increased in three group samples including healthy subjects,chronic pancreatitis,and pancreatic cancer.ABHD11-AS1 has a high diagnostic value for pancreatic cancer,especially for early pancreatic cancer,and is higher than tumor markers CEA,CA199 and CA125 and the diagnostic value of combined ABHD11-AS1 with tumor markers is further increased.In addition,the overall survival rate of patients with high expression of ABHD11-AS1 was significantly reduced compared with patients with low expression.Conclusion:There are lncRNAs expressed differentially in the plasma of patients with pancreatic cancer.The long non-coding RNA ABHD11-AS1 is one of which is upregulated in the plasma of patients with pancreatic cancer,and has the value of early diagnosis of pancreatic cancer,and has a higher diagnostic value in combination with tumor markers.It is expected to be a new biomarker for the early diagnosis of pancreatic cancer.